AC Immune Ltd (NASDAQ:ACIU) — Market Cap & Net Worth
Market Cap & Net Worth: AC Immune Ltd (ACIU)
AC Immune Ltd (NASDAQ:ACIU) has a market capitalization of $303.29 Million ($303.29 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14921 globally and #3359 in its home market, demonstrating a 0.34% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AC Immune Ltd's stock price $2.98 by its total outstanding shares 101773573 (101.77 Million). Analyse AC Immune Ltd cash conversion from operations to see how efficiently the company converts income to cash.
AC Immune Ltd Market Cap History: 2016 to 2026
AC Immune Ltd's market capitalization history from 2016 to 2026. Data shows change from $1.32 Billion to $303.29 Million (-15.86% CAGR).
Index Memberships
AC Immune Ltd is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #398 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1433 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.02% | #211 of 263 |
Weight: AC Immune Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
AC Immune Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AC Immune Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
89.44x
AC Immune Ltd's market cap is 89.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.32 Billion | $23.21 Million | -$7.10 Million | 56.91x | N/A |
| 2017 | $1.30 Billion | $20.25 Million | -$26.41 Million | 64.32x | N/A |
| 2018 | $961.76 Million | $7.19 Million | -$50.95 Million | 133.69x | N/A |
| 2019 | $867.11 Million | $110.46 Million | $45.44 Million | 7.85x | 19.08x |
| 2020 | $526.17 Million | $15.43 Million | -$61.92 Million | 34.10x | N/A |
| 2021 | $503.78 Million | $944.00K | -$73.00 Million | 533.66x | N/A |
| 2022 | $207.62 Million | $3.94 Million | -$70.75 Million | 52.76x | N/A |
| 2023 | $508.87 Million | $14.80 Million | -$54.23 Million | 34.38x | N/A |
| 2024 | $274.79 Million | $27.31 Million | -$50.92 Million | 10.06x | N/A |
| 2025 | $319.57 Million | $3.57 Million | -$67.28 Million | 89.44x | N/A |
Competitor Companies of ACIU by Market Capitalization
Companies near AC Immune Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to AC Immune Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
AC Immune Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, AC Immune Ltd's market cap moved from $1.32 Billion to $ 303.29 Million, with a yearly change of -15.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $303.29 Million | -5.10% |
| 2025 | $319.57 Million | +16.30% |
| 2024 | $274.79 Million | -46.00% |
| 2023 | $508.87 Million | +145.10% |
| 2022 | $207.62 Million | -58.79% |
| 2021 | $503.78 Million | -4.26% |
| 2020 | $526.17 Million | -39.32% |
| 2019 | $867.11 Million | -9.84% |
| 2018 | $961.76 Million | -26.17% |
| 2017 | $1.30 Billion | -1.39% |
| 2016 | $1.32 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of AC Immune Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $303.29 Million USD |
| MoneyControl | $303.29 Million USD |
| MarketWatch | $303.29 Million USD |
| marketcap.company | $303.29 Million USD |
| Reuters | $303.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About AC Immune Ltd
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins … Read more